Royalty Report: Diagnostic, Drugs, Assay – Collection: 237270

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Diagnostic
  • Drugs
  • Assay
  • Disease
  • ribonucleic acid
  • Biotechnology
  • Drug Discovery
  • Medical
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237270

License Grant
With this agreement, Licensor will supply MassARRAY Products and to design MassARRAY Assays for Licensee.

Licensor grants a nonexclusive, limited right to use, without the right to sublicense or otherwise permit third parties to use, the MassARRAY Kits, in conjunction with the MassARRAY System, for the defined Internal Research Purposes, within the Territory.

For MassARRAY Assays designed and developed solely by Licensor for either Non-Proprietary SNPs or for Proprietary SNPs that Licensee will not maintain Exclusive Rights to, Licensor grants a nonexclusive license, without sublicense or transfer rights, to use MassARRAY Assays designed and developed by Licensor in conjunction with the MassARRAY Products and MassEXTEND Methods and Processes, for Licensees Commercial Diagnostics Services, in the Territory.

For MassARRAY Assays designed and developed solely by Licensee, Licensor grants a nonexclusive license, without right to sublicense or transfer rights, to use MassARRAY Products and MassEXTEND Methods and Processes in conjunction with the MassARRAY Assays designed and developed by Licensee for Licensees Commercial Diagnostics Services, in the Territory.

For MassARRAY Assays jointly designed and developed by Licensor and Licensee, Licensor grants an exclusive license, limited to a period of eighteen ( 18) months from Assay validation, without  sub-license or transfer rights, to use MassARRAY Assays jointly designed and developed by Licensor and Licensee in conjunction with the MassARRAY Products and MassEXTEND Methods and Processes, for Licensees Commercial Diagnostics Services, in the Territory.

License Property
Licensor has developed proprietary MassARRAYâ„¢ technology for high-throughput DNA analysis.

MassARRAY Assay or Assay shall mean an assay for the purpose of genotyping a particular Proprietary SNP or Non-proprietary SNP or a group of more than one Proprietary or Non-Proprietary SNPs, and that may be used with MassARRA Y Products for performing MassEXTEND â„¢ Methods and Processes.

MassARRAY Products shall mean the MassARRAY System, the MassARRAY Kit, and the additional MassARRAY Consumables.

MassEXTENDâ„¢ Methods and Processes shall mean Licensors proprietary MassEXTENDâ„¢ reactions claimed under Patent Rights including United States Patent Application Serial No.09/287,679 related applications, and foreign equivalents thereof.

SNP shall mean a single nucleotide polymorphism.

MassARRayâ„¢ System SpectroREADER â„¢, high-speed mass spectrometer for separation, detection and characterization of the analyte molecules from a miniaturized array; configured with a workstation and post processing software.

Field of Use
Commercial Diagnostics Services shall mean developing, validating and performing in-house genotyping services in conjunction with a clinical diagnostic test to detect known disease mutations or known prognostic polymorphisms for Specialty customers.

Licensee has agreed, to use its best commercial efforts to utilize MassARRAY Assays for all of the clinical diagnostic areas of Aseptic Meningitis (Coxsackievirus A 7, 9, 10, 16 and B 1-6 RNA; Echovirus 4 9, 11~ 30 RNA; Mumps RNA);  Arbovirus (E. Equinine, W. Equinine, Lacrosse and St. Louis); Encephalitis (CMV, Influenz.a A/B, HSV ½);  Enterovirus RNA;  Histoplasma;  Aspergillus;  Pneumocystis;  Hepatitis C (genotype/subtype);  Hepatitis B (genotype);  and, HIV-1 (genotype).

IPSCIO Record ID: 5316

License Grant
Licensor grants to Licensee, for  the term of this Agreement, a non-transferable, non-exclusive license to use the SNP Assay Kits (provided under  this  Agreement) on DNAPrint's SNPstream Instrument solely for research use and only for the detection of genetic polymorphism by SNP-IT.  Licensee may make this use only on its own behalf and in its  provision of Genotyping Services under this Agreement.
License Property
Primer Extension means a nucleic acid template-dependent primer extension reaction to determine the identity of a single nucleotide base at a specific position in a nucleic acid of interest.

SNP Assay Kit means the SNPware(TM) pre-formatted consumable assay kits containing validated and quality controlled reagents or similar kits for genotyping.

Licensor Trademarks means the marks.

Field of Use
The rights granted relates to the Company providing Formatting with its supply of SNP Assay Kits to the Licensee.  Licensee may not order any SNP Assay Kit until the Company completes Formatting for the particular SNP(s) which the SNP Assay Kit is intended to identify.

IPSCIO Record ID: 211922

License Grant
This Agreement is to develop, manufacture, and commercialize innovative diagnostic systems integrating proprietary Licensor assays and technologies, and proprietary Licensee technologies and systems.

Pursuant to this agreement, The Belgian Licensor will have exclusive distribution rights in the territory.   If the R&D Collaboration results in development of a sample preparation cartridge for extraction of genomic DNA that does not incorporate proprietary Licensors technology and that is generically applicable for any procedure based on analysis of human genomic DNA, then Licensee agrees not to provide such cartridge for sale by another party to be licensed and approved for use in HLA apolipoprotein E, or CF gene (for cystic fibrosis) which are current market areas for Licensor; for a time period of (18) months.

License Property
The focus of this collaboration is the development of products integrating our proprietary technologies for sample preparation, rapid amplification and detection and Licensor's proprietary methods for genetic testing and viral genotyping.

Licensee has certain proprietary technology and experience relating to diagnostic assay reagents, protocols, and detection systems.

Products shall mean systems, subsystems, consumables, and software resulting from the R&D Collaboration and incorporating proprietary Licensee technology and proprietary Licensor technology, or systems, subsystems, and consumables incorporating proprietary Licensee technology that are specifically designed and produced according to Licensor approved Product Requirements and Specifications for use with proprietary Licensor technology and assay procedures.

Field of Use
The Field shall mean human diagnostics, as evidenced by regulatory labeling indicating approval for use in human diagnostics or for investigation of putative clinical utility by a diagnostics laboratory in a clinical research setting (e.g. For Investigational Use Only or For Research Use Only); food testing; and veterinary testing.

IPSCIO Record ID: 243464

License Grant
For the Conditional Non-Exclusive License to Licensee for Instruments, Licensor grants to a nonexclusive, world-wide license under Licensors interest in the Intellectual Property to make, have made, and import, Instruments outside of the Collaboration Field.

For the Non-Exclusive License to Licensee for Instruments Developed Outside the Joint Development Program, Licensor grants a non-exclusive, world-wide license under Licensors interest in Collaboration Licensors Intellectual Property to make, have made, use, import, offer to sell, and sell instruments outside the Collaboration Field.

For the Non-Exclusive License to Licensee for Instruments,  Licensor grants to a non-exclusive world-wide license under Licensors interest in the Intellectual Property to use, offer to sell, and sell Instruments outside of the Collaboration Field.

This agreement also includes exclusive grants from Licensee to Licensor.

License Property
Licensee has certain skills, proprietary technology and know-how related to the manufacture, design and use of Assembled Arrays.

Licensor has certain skills, proprietary technology and know-how related to the development of bioanalytical instrumentation systems and associated reagents and the marketing, sales and support of products incorporating such systems.

Licensor has DNA Synthesis and Purification Patents  referred to as the Caruthers Process and Caruthers Reagents, and related patents.

Field of Use
Collaboration Field means the field of Zip Code Chemistry used in combination with Assembled Arrays.

Nucleic Acid Analysis Field means the field of characterization of a nucleic acid sample including but not limited to the determination of the relative abundance of the nucleic acid, all or part of a sequence of the nucleic acid, or variations in the sequence of the nucleic acid. The Nucleic Acid Analysis Field excludes the Collaboration Field.

The Parties are designing product based on the Array of Arrays for SNP genotyping. The first SNP genotyping assay format that Licensee intend to commercialize will be PE Biosystems' proprietary OLA ZipCode assay format. This assay format enables the creation of a universal Array of Arrays that can be used to analyze any set of SNPs.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.